# AbbVie Acquires Apogee Therapeutics for $10.9 Billion

> ma · REPORTED · 2026-06-22

AbbVie announced a definitive all-cash agreement to acquire Apogee Therapeutics for $135.11 per share, totaling approximately $10.9 billion, a 49% premium to Apogee's closing price on June 18. The deal adds zumilokibart, a Phase 3 anti-IL-13 monoclonal antibody for atopic dermatitis and asthma, and multiple other clinical-stage immunology candidates to AbbVie's portfolio.

- Company: AbbVie
- Sector: biotech
- Primary source: https://www.sec.gov/Archives/edgar/data/0001551152/000110465926076067/tm2618365d1_ex99-1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.